Detalhe da pesquisa
1.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
Blood
; 141(2): 156-167, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714312
2.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
3.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755235
4.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
; 97(3): E83-E86, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34882831
5.
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.
Am J Hematol
; 96(4): E111-E114, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33448430
6.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Lancet Haematol
; 10(11): e902-e912, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914483
7.
Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.
Cancer Med
; 11(5): 1292-1298, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35106962
8.
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Blood Cancer J
; 12(1): 9, 2022 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075109
9.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Blood Adv
; 6(17): 5132-5145, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728048
10.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Lancet Haematol
; 9(2): e98-e110, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032434
11.
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Leukemia
; 35(1): 62-74, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32203138
12.
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
J Hematol Oncol
; 14(1): 59, 2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33849608
13.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Clin Pharmacokinet
; 51(12): 823-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018466